Page 32 - NobleCon19revC2_Neat
P. 32
Health Care
Date November 21, 2023 Health Care
52wk High $0.84
52wk Low $0.29 AIM ImmunoTech Inc. AIM $0.43
2117 SW Highway 484
Ocala, FL 34473
(USD - in millions) aimimmuno.com
Market Cap 20.2
Enterprise (0.8)
Basic Shares Out. 48.84 COMPANY OVERVIEW
Float 44.71
Institutional Holdings 8.86% Detailed Analysis:Channelchek.com
Short Interest 0.45
Avg. 90-Day Volume 0.12 AIM ImmunoTech Inc is an immuno-pharma company focused on
research and development of therapeutics to treat immune disorders,
viral and cancer diseases. AIM’s flagship products include Ampligen
(Rintatolimod), a drug of large macromolecular RNA molecules for
EPS Data cancer and viral diseases and drug Alferon N Injection for a category of
STD infection. Clinical trials of Ampligen include studies of cancer
2021 2022 2023 patients with renal cell carcinoma, malignant melanoma, colorectal
CQ1 (0.08) (0.06) (0.08) cancer, advanced recurrent ovarian cancer and triple negative
CQ2 (0.07) (0.09) (0.10) metastatic breast cancer.
CQ3 (0.08) (0.13) (0.16)
CQ4 (0.12) (0.09) (0.15)
CY (0.36) (0.37) (0.50) Source: Channelchek/QuoteMedia
Long-Term EPS Estimate N/A
Price/Book (mrq) 0.45
ROE (ttm) -63.63
Debt-to-Total Cap. (mrq) 3.21
Fiscal Year End 31-Dec
2117 SW HighOcala FL 34473
Key Executives
CEO: Equels, Thomas
CFO: Dickey, Robert
COO: Rodino, Peter
IR: Coverly, Ann Marie
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblecapitalmarkets.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
212.896.4625
Refer to the back of the book for disclosures
